Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study


      The effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in prostate cancer (PCa) patients is not well understood. We evaluated changes in CP after 6 months of medical castration with luteinizing hormone-releasing hormone (LHRH) analogues.

      Methods and Materials

      We performed a prospective, observational, multicenter, open-label study of PCa patients scheduled to receive LHRH analogues for ≥6 months. We assessed 4 domains of CP at baseline and after 6 months of ADT: (1) working memory, assessed with the Wechsler Adult Intelligence Scale III (WAIS III) Digit Span subtest; (2) visual memory, assessed with an ad hoc visual memory test; (3) visuospatial ability, assessed with the Judgment of Line Orientation test and Mental Rotation of Three-Dimensional Objects test; and (4) nonverbal analytical reasoning, assessed with the WAIS III Matrix Reasoning test. Changes outside the baseline 95% confidence intervals were considered significant.


      A total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test whereas 63 (20.4%) experienced significant changes on ≥1 test. Most of these patients showed a change on only 1 test, distributed evenly between improvement (58 patients, 18.8%) and worsening (56 patients, 18.2%). For individual tests, most patients (87.8%-91.8%) had no change from baseline; however, the significant changes (improvement vs deterioration) were as follows: WAIS III Digit Span subtest (6.3% vs 5.9%), visual memory (5.3% vs 5.7%), Judgment of Line Orientation test (5.3% vs 4.5%), Mental Rotation of Three-Dimensional Objects test (4.1% vs 4.1%), and WAIS III Matrix Reasoning test (4.8% vs 5.8%).


      CP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • López Torrecilla J.
        • Hervás A.
        • Zapatero A.
        • et al.
        Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
        Rep Pract Oncol Radiother. 2015; 20: 259-272
        • Heidenreich A.
        • Bastian P.J.
        • Bellmunt J.
        • et al.
        EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
        Eur Urol. 2014; 65: 467-479
        • McGinty H.L.
        • Phillips K.M.
        • Jim H.S.
        • et al.
        Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis.
        Support Care Cancer. 2014; 22: 2271-2280
        • Green H.J.
        • Pakenham K.I.
        • Headley B.C.
        • et al.
        Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial.
        BJU Int. 2004; 93: 975-979
        • Green H.J.
        • Pakenham K.I.
        • Headley B.C.
        • et al.
        Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial.
        BJU Int. 2002; 90: 427-432
        • Joly F.
        • Alibhai S.M.
        • Galica J.
        • et al.
        Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
        J Urol. 2006; 176: 2443-2447
        • Almeida O.P.
        • Waterreus A.
        • Spry N.
        • et al.
        One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
        Psychoneuroendocrinology. 2004; 29: 1071-1081
        • Jenkins V.A.
        • Bloomfield D.J.
        • Shilling V.M.
        • et al.
        Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
        BJU Int. 2005; 96: 48-53
        • Alibhai S.M.
        • Breunis H.
        • Timilshina N.
        • et al.
        Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.
        J Clin Oncol. 2010; 28: 5030-5037
        • Cherrier M.M.
        • Rose A.L.
        • Higano C.
        The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
        J Urol. 2003; 170: 1808-1811
        • Gonzalez B.D.
        • Jim H.S.
        • Booth-Jones M.
        • et al.
        Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: A controlled comparison.
        J Clin Oncol. 2015; 33: 2021-2027
        • Jim H.S.
        • Small B.J.
        • Patterson S.
        • et al.
        Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: A controlled comparison.
        Support Care Cancer. 2010; 18: 21-27
        • Mohile S.G.
        • Lacy M.
        • Rodin M.
        • et al.
        Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
        Crit Rev Oncol Hematol. 2010; 75: 152-159
        • Gómez F.C.
        • Piedmont R.L.
        • Fleming M.Z.
        Factor analysis of the Spanish version of the WAIS: The Escala de Inteligencia Wechsler para Adultos (EIWA).
        Psychol Assess. 1992; 4: 317-321
        • Benton A.
        • Hamsher K.
        • Varney N.
        • et al.
        Contributions to Neuropsychological Assessment: A Clinical Manual.
        Oxford University Press, New York1983
        • Woodard J.L.
        • Benedict R.H.
        • Roberts V.J.
        • et al.
        Short-form alternatives to the Judgment of Line Orientation Test.
        J Clin Exp Neuropsychol. 1996; 18: 898-904
        • Shepard R.N.
        • Metzler J.
        Mental rotation of three-dimensional objects.
        Science. 1971; 171: 701-703
      1. Wechsler D. Escala de Inteligencia de Wechsler Para Adultos–III [Wechsler Adult Intelligence Scale]. Manual de Aplicación y Corrección. Segunda Edición Revisada. Madrid, Spain: TEA Ediciones; 2001.

        • Pons J.I.
        • Matías-Carrelo L.
        • Rodríguez M.
        • et al.
        Estudios de validez de la Escala de Inteligencia Wechsler para Adultos Versión III, Puerto Rico (EIWA-III).
        Rev Puertorriquena Psicol. 2008; 19: 75-111
        • Jamadar R.J.
        • Winters M.J.
        • Maki P.M.
        Cognitive changes associated with ADT: A review of the literature.
        Asian J Androl. 2012; 14: 232-238
        • Nelson C.J.
        • Lee J.S.
        • Gamboa M.C.
        • et al.
        Cognitive effects of hormone therapy in men with prostate cancer: A review.
        Cancer. 2008; 113: 1097-1106


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.